Linneo Health and Phytocontrol Group sign exclusive collaboration
Linneo Health and the Phytocontrol laboratory enter into a unique collaboration. It marks an entry point for Phytocontrol into the Iberian market in the analysis of medicinal cannabis.
Through this collaboration, Linneo Health and Phytocontrol will exclusively develop improved methods for pesticide and active ingredient analysis, which will strengthen Linneo Health’s global reach and facilitate entry into new medicinal cannabis markets, including Israel – the world’s second largest medicinal cannabis market outside the US!
A unique collaboration
This agreement has enormous potential for both companies. It will allow Linneo Health to accelerate its growth and progress in the development of new cannabinoid profiles or matrix modifications, while facilitating Phytocontrol’s first step into the medicinal cannabis sector, with the possibility of future service collaborations between the two companies.
We’re delighted to be collaborating with Linneo Health in a partnership that not only provides us with a port of entry into the Iberian market, but also marks our first venture into the medicinal cannabis sector. We share Linneo’s belief in the commitment to quality in everything we do, and we look forward to the mutual benefits that this collaboration will bring to both our organisations – Mikaël BRESSON (CEO of Phytocontrol)
